Key Highlights

  • Synergy CHC disclosed a notice of default dated August 11, 2026, after missing an interest payment due August 3, 2026 with a cure period that expired August 6, 2026.
  • Outstanding principal under the term Loan Facility was approximately $17.6 million, excluding accrued interest, fees and expenses.
  • A separate forbearance agreement terminated as a result of the default, triggering a forbearance fee of $404,173.06.
  • The lender reserved the right to charge post-default interest, accelerate the obligations, and exercise other remedies under the loan documents.

Synergy CHC Corp. (NASDAQ:SNYR) has run into a serious balance-sheet problem. The consumer health and wellness company, known for brands in the nutrition and supplement space, disclosed in an August 2026 regulatory filing that it had received a notice of default on its term loan, putting a spotlight on its ability to manage Debt obligations that now exceed its market value.

For a small-cap company, a default notice is among the most consequential events that can hit the stock, because it can trigger acceleration of debt and force difficult financing or restructuring decisions. The headline question, whether the Equity can survive the latest financing pressure, now hinges on how Synergy resolves the standoff with its lender.

The Default, in Detail

In an 8-K describing an event dated August 11, 2026, Synergy disclosed that ACP Agency, LLC, the administrative and Collateral agent under its term loan Credit agreement dated May 30, 2025, had issued a notice of default. The trigger was a missed interest payment that had been due on August 3, 2026; the applicable cure period expired on August 6, 2026 without payment. Outstanding principal under the facility was approximately $17.6 million, excluding accrued interest, fees and expenses.

The default carried additional consequences. A separate forbearance agreement dated May 28, 2026 terminated on August 6, 2026 as a result of the event, and a forbearance fee of $404,173.06 became due and payable. The lender reserved its rights to charge interest at the post-default rate, accelerate the obligations, and exercise other remedies available under the loan documents, language that underscores the severity of the situation.

Business and Financial Position

Synergy operates in the consumer health and wellness market, where it markets branded products across nutrition and lifestyle categories. The company has historically carried Leverage relative to its size, and the missed payment and expired forbearance suggest the Cash Flow generated by the Business has not been sufficient to comfortably service the debt. With principal of roughly $17.6 million plus fees and post-default interest potentially in play, the Balance Sheet is now the dominant Factor in the Investment case, overshadowing product-level performance. A default of this kind can also trigger cross-default provisions in other agreements and complicate relationships with suppliers and partners.

The forbearance history is telling. The company had entered a forbearance agreement in late May 2026, which typically signals that a borrower and lender were already working through covenant or payment difficulties. When that arrangement terminated in early August after the missed payment, it removed the temporary protection the company had been operating under, leaving the lender's remedies fully in play.

Stock-Market Context

SNYR rose on August 27, 2026 amid the overhang from the default disclosure. Stocks in default situations typically trade with extreme Volatility as investors handicap the odds of a negotiated resolution, refinancing, dilutive Capital raise or more severe restructuring. The wide range of possible outcomes, from a forbearance extension to acceleration, makes the shares highly speculative.

The Lender Standoff Now Defines the Stock

The critical near-term catalysts are any communications about the lender relationship: a new forbearance agreement, a waiver, a refinancing, or an acceleration of the debt. Investors will be monitoring the company's liquidity, whether it can raise capital and on what terms, and any operational updates that speak to its ability to generate cash.

The risk of dilution or a distressed restructuring is a key consideration. Until Synergy demonstrates a credible path to curing the default or refinancing the facility, the financing pressure described in the filing is likely to remain the defining feature of the stock.